Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,196 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07780877 | Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer | not yet recruiting | Phase 2 | 85 | Fudan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07783022 | Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer | recruiting | — | 1,920 | Fudan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07776301 | Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast Cancer | recruiting | N/A | 225 | Fudan UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07776340 | Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC | not yet recruiting | Phase 2 | 104 | Fudan UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07776717 | TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma(TACTIC-RCC) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 0 | Aug 20, 2026 | clinicaltrials |
| NCT07777536 | Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer | recruiting | Phase 2 | 72 | Fudan UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04383275 | Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)(IRIS) | active not recruiting | Phase 2 | 367 | Fudan UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07771881 | Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer | not yet recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07768943 | GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 620 | Fudan UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07762885 | Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery | recruiting | Phase 3 | 636 | Fudan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07762924 | Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery | recruiting | Phase 2 | 234 | Fudan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07762976 | Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma | recruiting | Phase 2 | 148 | Fudan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07079462 | Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis | active not recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760844 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC(SCHBCC-N0117) | not yet recruiting | Phase 3 | 180 | Fudan UniversityOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT05468138 | PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery | active not recruiting | Phase 2 | 94 | Fudan UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07757165 | The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy(ESMGC) | recruiting | Phase 2 | 126 | Fudan UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07159048 | The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors | recruiting | N/A | 120 | Fudan UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07755423 | Stereotactic Body Radiotherapy for the Treatment of Distant Metastases in Thyroid Cancer: A Phase II Prospective Clinical Study | enrolling by invitation | — | 44 | Fudan UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06447636 | Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06221423 | Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer | withdrawn | — | 0 | Fudan UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07268131 | TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria(TITAN-HCC) | recruiting | N/A | 30 | Fudan UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06914687 | Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07522879 | A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma(MRG003-SACC) | recruiting | Phase 2 | 40 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07727343 | AI-Guided TURBT for Bladder Cancer(AITURBT) | not yet recruiting | N/A | 170 | Fudan UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT05575804 | GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 32 | Fudan UniversityOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07441369 | Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer | enrolling by invitation | Phase 2 | 16 | Fudan UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04537286 | First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients | completed | Phase 2 | 90 | Fudan UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07207824 | DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC(HERO) | recruiting | Phase 3 | 182 | Fudan UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07692230 | MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer | active not recruiting | — | 2,000 | Fudan UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07716046 | Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer(FACET) | not yet recruiting | Phase 2 | 240 | Fudan UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT04706598 | Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment | active not recruiting | Phase 1 / Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05531123 | Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer | active not recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06187506 | Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer | active not recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07711977 | Efficacy of Acupuncture for Postoperative Urinary Retention Following Radical Hysterectomy for Cervical Cancer(APOUR) | not yet recruiting | N/A | 324 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 0 | Jul 17, 2026 | clinicaltrials |
| NCT07708922 | Nectin-4 PET to Predict Response to Nectin-4-Targeted Therapy in Advanced Breast Cancer | active not recruiting | — | 40 | Fudan UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708935 | Real-World Study of Young Patients With Solid Tumors in China | recruiting | — | 12,000 | Fudan UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07182721 | SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment(SHINE-HER) | recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705438 | Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC | recruiting | — | 30 | Fudan UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06889610 | A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. | recruiting | Phase 2 | 95 | Fudan UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07117630 | An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07697859 | PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC(ESO-shanghai31) | recruiting | — | 354 | Fudan UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07614828 | Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in Malignant Melanoma of Nasal and Paranasal Mucosa | withdrawn | Phase 2 | 0 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695532 | A Clinical Risk Score to Stratify High-risk PanNETs | completed | — | 552 | Fudan UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06547710 | Primary Tumor Resection for M1a Stage Lung Cancer(ECTOP-1023) | recruiting | — | 66 | Fudan UniversityOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06636591 | Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer | completed | N/A | 14 | Fudan UniversityOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07459309 | Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies | recruiting | N/A | 20 | Fudan UniversityOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07528716 | Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy | recruiting | Phase 3 | 280 | Fudan UniversityOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06161922 | Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy | completed | — | 600 | Fudan UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07082049 | AI-LLM Communication Aid in Prostate Cancer Care (AI-CAP)(AI-CAP) | active not recruiting | N/A | 160 | Fudan UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07403136 | Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC | recruiting | Phase 2 | 104 | Fudan UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials